What is the recommended management for acute, subacute, and chronic subdural hematomas?

Management of Subdural Hematoma

Management of subdural hematoma depends critically on whether it is acute, subacute, or chronic, with acute subdural hematomas (aSDH) requiring emergency surgical evacuation when symptomatic or meeting size criteria, while chronic subdural hematomas (cSDH) can often be managed with burr-hole drainage or increasingly with middle meningeal artery embolization.

Acute Subdural Hematoma (aSDH)

Surgical Indications

Proceed with emergency craniotomy for aSDH when:

• Thickness >10mm or midline shift >5mm on CT
• GCS decline of ≥2 points from injury to hospital admission
• Asymmetric or fixed/dilated pupils
• Intracranial pressure >20 mmHg

The surgical approach varies significantly between centers, with acute surgery rates ranging from 7-52% and primary decompressive craniectomy (versus craniotomy) ranging from 6-67% 1. This substantial variation (median odds ratio of 1.84 for surgery and 2.68 for decompressive craniectomy) reflects ongoing uncertainty about optimal surgical technique, though both approaches aim to decompress neural tissue and restore perfusion 2.

Conservative Management Considerations

For small aSDH without mass effect or neurological decline, observe with:

• Serial neurological examinations every 2-4 hours initially
• Repeat CT at 24 hours to assess for expansion
• Critical caveat: 2.8% of conservatively managed aSDH transform into cSDH requiring delayed surgery within 180 days 3

High-risk features for transformation to cSDH include:

• Absence of other traumatic pathology
• Male sex
• Liver disease
• Coagulopathy or anticoagulant use
• Patients with PERSIST score ≥48 have 7.1% transformation risk (10-fold higher than low-risk patients) 3

Anticoagulation Management in aSDH

For patients on anticoagulation with negative initial CT:

• Warfarin patients: Delayed intracranial hemorrhage occurs in only 0.6%, with observation alone reasonable if initial CT negative 4
• Clopidogrel patients: Zero delayed ICH in studied cohorts with negative initial CT 4
• Do not routinely admit for observation or reverse anticoagulation if initial CT is negative 4

However, if initial CT shows aSDH, reverse anticoagulation immediately and hold antithrombotic agents during acute phase.

Subacute Subdural Hematoma

This transitional phase (3-21 days post-injury) presents unique challenges:

Surgical approach depends on hematoma consistency:

• Solid clot beneath dura with liquid component near brain: Requires small craniotomy or full craniotomy 5
• Liquefied hematoma: Burr-hole drainage may suffice 5

Key imaging findings on MRI:

• FLAIR sequences show irregularly shaped hematoma with gyrus patterns
• Diffusion-weighted imaging demonstrates two-layered structure (solid and liquid components) 5

Surgical planning: If diffusion-weighted MRI shows solid clot component, plan for craniotomy rather than burr-hole, as the latter has higher failure rates 5.

Chronic Subdural Hematoma (cSDH)

Primary Treatment Options

First-line surgical intervention:

• Burr-hole drainage remains standard of care for symptomatic cSDH
• Single or double burr-holes with closed drainage system
• Success rate >80% for initial evacuation

Emerging alternative: Middle meningeal artery (MMA) embolization

• Increasingly used as adjunctive therapy or stand-alone treatment 6
• Consider MMA embolization as primary treatment for:
  • High surgical risk patients (frail, elderly, multiple comorbidities)
  • Recurrent cSDH after surgical evacuation
  • Bilateral cSDH
• Evidence shows it is safe and effective, with expanding indications 6

Recurrence Prevention

Recurrence rates approach 10-30% after initial drainage. To minimize recurrence:

• Use subdural drain for 24-48 hours post-operatively
• Consider MMA embolization as adjunct in high-risk patients
• Avoid rapid brain re-expansion (controlled drainage)

Antithrombotic Medication Restart Timing

This requires individualized risk-benefit assessment balancing thrombosis versus rebleeding:

For patients requiring anticoagulation:

• Hold antithrombotics for minimum 4 weeks post-evacuation if thrombotic risk is moderate
• Restart at 1-2 weeks only if very high thrombotic risk (mechanical valve, recent stroke/MI, atrial fibrillation with CHADS-VASC ≥4)
• Prefer antiplatelet agents over anticoagulation when possible during first 3 months
• Obtain repeat CT before restarting to confirm hematoma resolution 6

Common Pitfalls to Avoid

1. Assuming all aSDH require surgery: Small hematomas without mass effect can be observed, but require close monitoring and 24-hour repeat imaging
2. Using burr-holes for subacute SDH with solid clot: MRI diffusion-weighted imaging should guide surgical approach; solid components require craniotomy 5
3. Premature anticoagulation restart: Rebleeding risk remains elevated for 4-6 weeks; balance carefully against thrombotic risk 6
4. Discharging high-risk aSDH patients too early: Those with PERSIST score ≥48 need enhanced surveillance for cSDH transformation 3
5. Overlooking MMA embolization: This is no longer experimental and should be considered for recurrent cSDH or high-risk surgical candidates 6